ArticleEJNMMI physics2025
Feasibility study of
Article in EJNMMI physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the safety and efficacy ofEuropean radiology experimental · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeActinium-225 (²²⁵Ac)-labeled prostate-specific membrane antigen (PSMA) radiopharmaceuticals represent a promising therapeutic approach for metastatic castration-resistant prostate cancer (mCRPC), yet clinical implementation remains limited by the absence of accurate dosimetric assessment methods. The complex decay chain and non-imaging alpha emissions of ²²⁵Ac pose substantial challenges for quantitative imaging. We aimed to evaluate the feasibility of quantitative single photon emission computed tomography (SPECT)-based dosimetry for ²²⁵Ac-PSMA-CY313 therapy by exploiting gamma emissions from daughter radionuclides francium-221 (²²¹Fr) and bismuth-213 (²¹³Bi).
methodsFour mCRPC patients received 185.8 ± 11.7 µCi ²²⁵Ac-PSMA-CY313 and underwent multi-timepoint SPECT/CT and whole-body planar imaging at 6, 24, 48, and 96 h post-injection. Quantitative SPECT reconstruction used ordered-subsets expectation-maximization with comprehensive corrections for attenuation, scatter, resolution blur, and crosstalk. Volume of interest were defined using co-registered ¹⁸F-PSMA-CY313 positron emission tomography /computed tomography (PET/CT). Time-activity curves were fitted with mono- or bi-exponential models, and absorbed doses were calculated using validated Monte Carlo-based software and International Commission on Radiological Protection reference phantoms.
resultsHigh-quality quantitative imaging was successfully achieved across all timepoints. Among normal organs, kidneys and liver exhibited the highest absorbed doses (1.55 ± 0.38 Gy and 1.07 ± 0.19 Gy, respectively), corresponding to dose coefficients of 0.23 ± 0.07 Gy/MBq and 0.16 ± 0.03 Gy/MBq. Soft-tissue lesions exhibited higher absorbed doses than bone metastases (5.03 ± 5.51 Gy versus 1.61 ± 2.28 Gy), with corresponding dose coefficients of 0.73 ± 0.80 Gy/MBq and 0.25 ± 0.33 Gy/MBq. Tumor-to-critical organ dose ratios indicated favorable therapeutic windows, with red marrow showing the highest ratio (14.84), followed by adrenal glands (6.35) and salivary glands (4.96), while the dose-limiting kidneys demonstrated a ratio of 1.55.
conclusionQuantitative SPECT-based dosimetry for ²²⁵Ac-PSMA-CY313 therapy is clinically feasible using standard imaging systems. This methodology demonstrates preferential tumor targeting with acceptable organ-at-risk dose distributions, supporting the therapeutic potential of ²²⁵Ac-PSMA-CY313 for mCRPC and providing a practical framework for personalized dosimetry in targeted alpha therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.